Porton Passed FDA cGMP Inspection with No Action Indicated（NAI）
On July 16, 2024, Porton Pharma Solutions Ltd. (hereinafter referred to as “Porton”, “the company”, “We”) announced that its Chongqing Changshou Site (CQ2) had undergone a cGMP (current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration (hereinafter referred to as “FDA”) from March 25 to 29, 2024. This cGMP inspection covered […]
Porton Passed FDA cGMP Inspection with No Action Indicated（NAI） Read More »